Ticker: SRRK

Company: Scholar Rock Holding Corporation (NASDAQ: SRRK) Recent Developments: In April 2025, David Hallal was appointed CEO following Jay T. Backstrom's transition to Senior Advisor. Scholar Rock announced positive top-line data from the Phase 2 EMBRAZE trial evaluating apitegromab for preservin...

Company Overview: Scholar Rock Holding Corporation (NASDAQ: SRRK) is a late-stage biopharmaceutical company focused on developing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. The company is recognized for its proprietary platform technol...